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Abstract
Background: Although disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of treatment for
inflammatory rheumatic diseases, medication adherence to DMARDs is often suboptimal. Effective interventions to
improve adherence to DMARDs are lacking, and new targets are needed to improve adherence. The aim of the
present study was to explore patients’ barriers and facilitators of optimal DMARD use. These factors might be used
as targets for adherence interventions.
Methods: In a mixed method study design, patients (n = 120) with inflammatory arthritis (IA) completed a
questionnaire based on an existing adapted Theoretical Domains Framework (TDF) to identify facilitators and
barriers of DMARD use. A subgroup of these patients (n = 21) participated in focus groups to provide insights into
their facilitators and barriers. The answers to the questionnaires and responses of the focus groups were
thematically coded by three researchers independently and subsequently categorized.
Results: The barriers and facilitators that were reported by IA patients presented large inter-individual variations.
The identified barriers and facilitators could be captured in the following domains based on an adapted TDF: (i)
knowledge, (ii) emotions, (iii) attention, memory, and decision processes, (iv) social influences, (v) beliefs about
capability, (vi) beliefs about consequences, (vii) motivation and goals, (viii) goal conflict, (ix) environmental context
and resources, and (x) skills.
Conclusions: Patients with IA have a variety of barriers and facilitators with regard to their DMARD use. All of these
barriers and facilitators could be categorized into adapted domains of the TDF. Interventions that address individual
facilitators and barriers, based on capability, opportunity, and motivation, are needed to develop strategies for
medication adherence that are tailored to individual patient needs.
Keywords: Medication adherence, Inflammatory arthritis, Theoretical Domains Framework, Disease modifying anti
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Background
Inflammatory arthritis (IA) is a long-term autoimmune
disease that is characterized by pain, swollen joints, bone
damage, and disability [1–3]. The most common condi-
tions of IA are rheumatoid arthritis (RA), ankylosing
spondylitis (AS), and psoriatic arthritis (PsA). Inflamma-
tory arthritis, especially RA and PsA, can cause joint
damage without proper and early treatment, and early
guided treatment with disease-modifying anti-rheumatic
drugs (DMARDs) is often recommended [4–8]. The new
paradigm in inflammatory arthritis, is to treat to target
(T2T), involving regular disease activity monitoring,
ideally using the most recently described composite
measures and remission criteria [9, 10]. The full benefits
of DMARDs can be achieved if patients strictly follow
drug regimens [11–14]. However, rates of adherence to
prescribed medications in patients with IA are subopti-
mal and vary widely from 3 to 93 % [15–22]. Therefore,
interventions to improve medication adherence are war-
ranted, but current interventions to improve adherence
are often complex and not very effective [12, 23]. To
discover possible intervention targets, more insights into
patients’ motivations to take or not take their medica-
tions are essential [24, 25].
Theoretical models may be useful for systematically ex-
ploring possible drivers of non-adherence and finding cor-
responding intervention strategies that target these drivers
[26–28]. Although different models have been applied to
medication adherence, none of these individual models
have been satisfactory for identifying barriers that result in
non-adherence [28–33]. A possible explanation might be
that the applied models, such as the Health Belief Model
[34], Theory of Reasoned Action [35], Theory of Planned
Behaviour [36], and Social Cognitive Theory [37], were
developed to understand, explain, or predict behav-
iours. However, to develop useful interventions for ad-
herence, other models or theoretical constructs are
needed that are particularly relevant to changing be-
haviour. This means that some essential domains, such
as skills [38] or the environment [39], may be over-
looked by some theories. To develop a model that con-
tains many domains that could be associated with
different behaviour theories, including theories that
focus on behavioural change, the Theoretical Domains
Framework (TDF) could be helpful. The TDF [40]
poses 12 theoretical domains that are based on 33
health behaviour theories (see Additional file 1). The
TDF covers a broad spectrum of individual and organ-
isational theories. Thus, it limits the risk of omitting
important areas when exploring factors that may im-
pact adherence to DMARD treatment. With regard to
medication adherence, the TDF has only been applied
in a study of barriers to medication adherence in car-
diovascular disease. This resulted in an adapted version
of the TDF that contains ten of the 12 original TDF do-
mains [25], the Identification of Medication Adherence
Barriers Model (IMAB; see Fig. 1).
To obtain more insights into patients’ drivers that re-
sult in adherence and non-adherence, the aim of the
present study was to identify both facilitators and bar-
riers of DMARD use in IA patients using an adapted
version of the TDF that was designed for medication ad-
herence (IMAB). Although the IMAB was developed to
identify medication adherence barriers, the present study
focused on identifying facilitators as well using the same
domains of this model.
Fig. 1 COM-B, derived from the Behaviour Change Wheel [45], TDF [40], and IMAB [25]
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Methods
The results of this mixed method study are reported ac-
cording to the Consolidated criteria for reporting qualita-
tive research (COREQ) [41].
Design
The study consisted of two phases: (1) a cross sectional
survey using a questionnaire that assessed facilitators and
barriers of medication use in patients with IA who were
using DMARDs, and (2) focus groups with a subgroup of
Phase 1 patients to provide in-depth understanding of the
identified facilitators and barriers. The aim was to first
identify barriers and facilitators of DMARD use in a large
group of IA patients by sending out questionnaires and
then use these answers in smaller focus group sessions
(10–15 patients) to discuss, elaborate upon, and deepen
the understanding of the raised barriers and facilitators.
until thematic saturation occurred.
Participants
Patients (n = 285) who were registered in the outpatient
pharmacy of the Sint Maartenskliniek (Nijmegen, The
Netherlands) were invited by mail to participate in this
study according to a random sampling method. The in-
clusion criteria were the following: (1) adult (>18 years
old) IA patients who used DMARDs and (2) ability to
read and write in Dutch. No exclusion criteria were
applied. Both early and established IA patients were
eligible to participate in the study. The written invitation
consisted of a letter with a description of the study, a
questionnaire with open-ended questions, and an invita-
tion to participate in the focus groups. To assess the ad-
herence of the patients to DMARDs, the Compliance
Questionnaire on Rheumatology (CQR) was applied.
Self-addressed stamped envelopes were provided for the
patients to return the questionnaires.
Procedure
Phase 1: questionnaires in patients with IA who used
DMARDs
The questionnaire comprised 18 open-ended questions
that covered the ten IMAB domains, derived from the
TDF (Table 1). The questions were formulated by the re-
searchers (MV, BvdB, and SvD) and pilot-tested through
a think-aloud procedure [42] by seven patients with IA,
ten people without IA, and two psychologists. The ques-
tionnaire allowed the patients to add new domains in
cases in which a construct did not fit in any of the exist-
ing domains (“Is there anything that influences the use
of your medication that is not represented by one of the
presented domains?”).
Phase 2: focus groups with a subgroup of phase 1 patients
All of the patients who participated in the focus groups
had previously completed the questionnaire in Phase 1,
and were already sensitized to the research topic and
IMAB domains. This so-called sensitization process
was meant to enhance the quality and quantity of the
patients’ contributions in the later focus group sessions
[43]. The patients who accepted this invitation were
randomly selected to participate in one of the focus
groups. A pilot focus group was not conducted, since
Table 1 Summary of questions with corresponding IMAB
domains
Domain Interview question
Knowledge What would you like to know about your
medication to take them (or inject them)
as prescribed by your physician?
Emotions Which emotions are evoked by the use of
your medication?
Attention, memory, and
decision process
Are you preoccupied with your medication?
Do you sometimes, on purpose or accidently,
forget your medication?
Do you feel sufficiently involved in the decision
making process surrounding your medication?
Social influences In which way does your physician play a
role in the use of your medication, other
than prescribing them?
Does any other health professional (like your
pharmacist or your RA nurse practitioner)
play a role in the use of your medication?
Does your family or do your friends play a
role in the use of your medication?
Does your work environment (colleagues or
supervisors) influence your medication use?
Beliefs about capabilities In which situations do you find it difficult to
use your medication?
Beliefs about
consequences
According to you, what could be the
consequences of taking (or injecting) your
medication?
According to you, what could be the
consequences of NOT taking (or injecting)
your medication?
Motivation and goals What is an important goal (or an important
personal motivation) for you to take (or
inject) your medication?
What is an important goal (or an important
personal motivation) for you NOT to take (or
inject) your medication?
Goal conflict What is helpful to you in daily life to be able to
take or inject your medication the right way?
Which daily hassles prevent you sometimes
from taking (or injecting) your medication?
Environmental context
and resources
Is the use of your medication sometimes
influenced by the ordering, retrieving,
delivery, prescribing, and/or reimbursement
of your medication?
Skills According to you, what is important for a
patient with RA to be able (physically as well
as mentally) to take (or inject) the medication
well?
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patients were involved in the development of the ques-
tions and sensitized by filling out the questionnaire.
The duration of the focus group sessions was 2 h, and
they were conducted at Sint Maartenskliniek. Two re-
searchers led each focus group. In the first focus group,
one female researcher (AH) facilitated plenary conver-
sations, and another female researcher (MV) studied
the group process and took notes. Two breakout ses-
sions were led by two female researchers (MO and
AH). The second focus group was organised similarly,
with the exception that the breakout sessions were led
by one female researcher (AH) and one male researcher
(BvdB). After introducing all of the participants in the
focus group, the aim of the group discussion was clari-
fied, namely to identify potential barriers and facilita-
tors of DMARD use. After the domains of the model
were introduced and explained, the group was divided
into two breakout groups. Each subgroup was given
45 min to explore five of the ten domains of the IMAB,
with a focus on identifying barriers and facilitators for
each domain. In the plenary session, after the breakout
session, all of the barriers and facilitators that were
identified in the subgroups were discussed. The patients
were then asked if they could think of any additional
barriers or facilitators that did not fit in one of the
presented domains, such that new domains could be
added.
Analysis
Both focus groups were audiotaped with consent from
all of the patients and transcribed verbatim. Descrip-
tive statistics were computed (means, standard devia-
tions, and frequencies where appropriate). To ensure
the patients’ privacy, all identifying information was
anonymised. All patients in the focus group read the
transcripts and were given the opportunity to discuss
changes they felt were needed before coding the tran-
scripts (member check). The answers of the question-
naire and the content of the transcripts was then
thematically analysed [44] to identify themes and sub-
themes that reflected facilitators and barriers for ad-
herence and non-adherence. The notes that were taken
during the breakout sessions were also analysed. Three
researchers (MV, JV, and BvdB) independently coded
the data and categorized the codes into themes and
subthemes using the IMAB model. The coding process
was discussed until consensus was reached among the
researchers.
To facilitate a future implementation process, the bar-
riers and facilitators that were identified with the corre-
sponding IMAB domains were categorized according to
the components of the Behaviour Change Wheel [45]:
Capability, Opportunity, and Motivation (COM). In this
behaviour system, these three components interact to
generate Behaviour (COM-B; Fig. 1).
Results
One hundred twenty of the 285 patients (42 %) returned
the questionnaire The mean age of the patients that
returned the questionnaire was 59.6 years (SD = 15.4 years),
and 60 % of the patients were female. Most of the patients
had RA (71 %). DMARD adherence according to the CQR
was 68 % (Table 2).
The subgroup of patients in the focus groups was com-
parable with regard to mean age (59.44 years, SD =
9,4 years). Of the patients in the focus groups, 85 % were
female, and most of the patients had RA (88 %). DMARD
adherence according to the CQR was 43 %.
Table 3 summarizes the identified barriers and facili-
tators for IA patients (by the respondents of the ques-
tionnaire and the participants of both focus groups)
with regard to DMARD use, categorized according to
the IMAB model and COM-B core components that
were derived from the Behaviour Change Wheel [45].
The Attention, Memory, and Decision Process domain
was split into two separate domains based on consensus
between the three researchers (“Memory and Atten-
tion” and “Decision-making process”) to accommodate
the categorization of all of the identified barriers and
facilitators. Several of the identified barriers and facilita-
tors were categorized into more than one IMAB domain
Table 2 Patient characteristics
Patients
(n = 285)a
Age, years (SD) 59.6 (±15.4)
Female, n (%) 171 (60 %)
Diagnosis:
Rheumatoid arthritis 201 (71 %)
Rheumatoid factor (RF positive+) 140 (70 %)
Anti-citrullinated Protein antibodies Positive (Anti-CCP+) 114 (54 %)
Psoriatic arthritis 49 (17 %)
Juvenile idiopathic arthritis 12 (4 %)
Other diagnoses 23 (8 %)
Pharmacological therapy, n (%)
Methotrexate 239 (84 %)
Sulphasalazine 7 (2 %)
Leflunomide 8 (3 %)
Hydroxychloquine 52 (18 %)
Glucocorticosteroid 29 (10 %)
Biological DMARDs 81 (28 %)
aQuestionnaires were processed anonymously. The patient characteristics that
are presented in the table were gathered from the patients that filled out
the questionnaire
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Table 3 IMAB domains and corresponding facilitators and barriers categorized according to COM-B components
COM-B Domain Facilitators Barriers
Capability Knowledge Knowledge of treatment effect
Information about necessity
Information about alternative medication
Information about experiences from others
Knowledge of how to administer medication
Knowledge of side effects
Knowledge of cost of medication
Skills Cognitive abilities
Coping strategies
Communication skills
Fine motor skills
Insufficient cognitive, communicative, or physical
skills to understand and/or administer medication
Memory and Attention Treatment effect
Aids (to remember)
Social support
Embedded in daily routine
Lack of daily routine
Experiencing side effects
Forgetting to take medication
Change of appearance of medication
Impact on lifestyle
Lack of treatment effect
Decision-making process Self-management (patient decides)
Satisfying relationship with health professional
(communication and trust)
Lack of involvement of health professional (health
professional decides, no shared decision making)
Doubting own knowledge
Influence of health insurance companies
Opportunity Environmental context
and resources
Logistics (having medication in stock)
Access to health professionals
Quality of product (needle)
Logistics (medication storage temperature,
pharmacy has no stock)
Cost of medication
Travelling (clearing injectable medications through
customs)
Change of name or appearance of medication
Social influences Health professionals (rheumatologist, pharmacist, nurse,
general practitioner): capabilities, trust, and empathy
Health insurance company: reimburses medication,
provides clear information
Family and friends: support adherence, support in
choices of medication, instrumental support
Colleagues: support, understanding
Lack of support from colleagues (incomprehension,
negative reactions)
Motivation Beliefs about capabilities Aids (to use, to remember)
Self-efficacy
Good (overall) health status
Difficulty in adherence because of social and work
events
Lack of daily routine
Worse health status
Difficult to inject
Experience of side effects
Doubting own knowledge with regard to
medication (as barrier to adherence)
Beliefs about
consequences
Belief of treatment effect
Belief of being able to better participate (social, work)
Experience of (long- and short-term) side effects
Belief that medication will be harmful: higher
disease activity
Lack of belief in efficacy
Dependency on medication
Less acceptance of (long-term) medication
Non-acceptance of diagnosis
Emotions Joy
Gratitude
Hope
Confidence
Anxiety
Sadness
Anger
Dependency on medication
Irritation
Incomprehension
Disparity
Powerlessness/helplessness
Insecurity
Feeling overwhelmed
Feeling crestfallen
Grief
Embarrassment
Regret
Stress
Disappointment
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because of the multifaceted nature of these factors. All of
the barriers and facilitators that were collected could be
categorized in the presented domains. No new, additional
domains were mentioned by the focus groups, which sup-
ported the data received from the respondents of the
questionnaire.
Capability
Capability, the first COM-B component, reflects the in-
dividual’s psychological and physical capacity to engage
in the activity concerned [45]. Capability encompassed
the following domains: Knowledge, Skills, Memory and
Attention, and Decision-making Process.
Knowledge
Knowledge about DMARD use was considered both a
barrier and a facilitator of adherence. Information about
how to administer the medication, general information
(also about alternative medications), and information
about necessity and the time to onset of effect of
DMARD use were mentioned frequently as facilitators
of DMARD use. Knowledge of side effects and the cost
of some of the medications were perceived as barriers.
Some patients sometimes felt guilty using expensive
medications, and they felt that they were a burden to so-
ciety. Thoughts and doubts about how precisely the
medication acts on the body were also mentioned as a
potential barrier:
“….You do not know how these medications exactly act
in your body. Yes, they tend to decrease the disease
activity, but you need to know how the medication
works. It maybe goes beyond my knowledge, but surely
it must be achievable to translate this information in
a simple way. I think that would help to accept that
you can take or inject this medication…”. Female,
63 years, diagnosed with RA in 2015
Clear and understandable instruction inserts were found
to facilitate adherence.
Skills
Patients mentioned that having acquired appropriate
coping skills to manage the disease and its medication
were facilitators for medication adherence. Examples
were given, such as being able to accept the fact that
they had to use their medication probably for the rest of
their lives. Cognitive abilities were also reported by the
patients as facilitators, such as being able to dose their
medication, understand which day of the week they need
to take certain medications, or being able to distinguish
between different medications. Lacking these abilities
was seen as a barrier to medication adherence. Several
barriers, such as how to open the package of the medica-
tion or difficulties with opening the tap to get water for
medication, were also mentioned. These physical abilities
were referred to as “fine motor skills.” Communication
skills were considered to be crucial, such as being able
to communicate in a timely manner with the rheuma-
tologist about side effects when these side effects pre-
vented patients from using the prescribed medication.
Memory and attention
Patients mentioned that incorporating the intake of their
medication in their daily routines was a great help. Aids,
such as an alarm on their smartphone or help from a
family member to remind them to take the medication,
were sometimes used. Experiencing beneficial effects of
the medication facilitated adherence to medication use.
Table 3 IMAB domains and corresponding facilitators and barriers categorized according to COM-B components (Continued)
Desolation
Despair
Agitation
Motivation and Goals Improvement of Quality of Life
Treatment effect
Social participation (including work)
Improvement of life expectancy
Better relationship with health professional
Maintain autonomy
Worse health status/wellbeing
Side effects
Comorbidity
Complexity of regimen
Resistance of need for medication
Denial of existence of illness
Difficulty administering medication
Lack of daily routine
Goal conflict Embedded in daily routine
Treatment effect leading to active social
participation (e.g., work)
Instrumental support (aids, information)
Social support
Method of administration (intravenous or low
frequency)
Stock (always available)
Experiencing side effects
Restrictions due to using medication (no alcohol)
Worse well-being (mentally and/or physically)
Not able to participate (social, work)
Distracted from taking medication
Lack of social support
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“They prescribed it, I took it and it went very well.
Then I have something to hold on to. If I continue,
then all will be great. That is what happened.”
Female, 75 years, diagnosed with RA in 2009
Social support was mentioned as a facilitator as well.
Support from family, friends, and colleagues was consid-
ered very essential by all of the patients.
Several barriers of DMARD use were mentioned by
the patients, including the absence of a daily routine,
experiencing side effects of the medication, forgetting
to take the medication, and a lack of efficacy of the
medication. Another barrier was related to the appear-
ance or name of the medication. For example, changing
the colour or name of the medication was considered
confusing and potentially dangerous. The patients also
considered the impact of the medication as intruding
on their lifestyle, such as not being able to consume al-
cohol on certain days because of the medication, which
was felt as patronizing and limiting social activities.
Decision-making process
The patients mentioned that the physician plays an im-
portant role as a facilitator for adherence, specifically in
the decision-making process. A good relationship with
the treating physician was considered crucial for trust
and communication about disease management, includ-
ing adherence. The patients reported that if they have
self-management skills, then a shared decision-making
process was considered a natural process, subsequently
leading to a more equal relationship with the physician
and better adherence. However, potential barriers to ad-
herence were mentioned by the patients, such as a lack
of interest and lack of competence by the physician to
involve the patient in the treatment regimen or a lack of
competence and lack of interest by the patient, which
would hamper the patient’s involvement as a partner in
the treatment.
“You need to be taken seriously. A little bit of
interaction. Of course you need to trust the abilities
of your physician, but it wouldn’t hurt to be critical
in a positive way…” Male, 47 years, diagnosed with
RA in 2011
The influence of health insurance companies was also
mentioned as a potential barrier by the patients, specific-
ally the possibility of a changing reimbursement policy
that may influence the adherence or non-adherence to
DMARDs.
Opportunity
Opportunity, the second COM-B component, reflects all
of the factors that lie outside the individual that make
the behaviour possible or prompt it [45]. Opportunity
encompassed the following domains: Environmental Con-
text and Resources and Social Influences.
Environmental context and resources
Access to the rheumatologist when needed was felt as
an essential facilitator for the patients. Another facilita-
tor that was discussed by the patients was logistics. The
prescribed medication should be in stock in the phar-
macy. Logistics was also mentioned as a barrier in cases
in which the pharmacy did not have the medication in
stock. Another barrier was the quality of the products,
such as the needles for injections. The patients com-
plained that the needles were too blunt. Additionally,
clearing injectable medications through customs while
travelling abroad and situations in which the storage
temperature could not be controlled were also perceived
as barriers.
“Going on holiday, taking your injections with you, and
the temperature should not exceed above 25 C, that is a
disaster. Then I think: the pharmacist should provide a
little cool box with these kind of medications”……
Female, 63 years, diagnosed with RA in 2015
The cost of medication was also mentioned as a barrier,
but the patients stated that they would be willing to pay a
small amount for the medication if it was not covered by
their insurance in order to obtain them.
Social influences
Support from the social environment of the patient was
mentioned as a facilitator. One example that was related
to the private environment was mentioned in one of the
focus groups:
“Sometimes, when I am feeling good, I think, ‘I just skip
my medication.’ but my husband always pushes me:
‘You have to take your medication just as usual.’ But,
still, I find it difficult (to take my medication always)…”
Female, 64 years, diagnosed with RA in 2000
Therefore, the patients reported that support from fam-
ily and friends could be helpful to stimulate adherence.
This support could be provided by discussing treatment
options or by giving instrumental support, such as helping
administer the medication.
The patients experienced an understanding of their
disease from their social network. They indicated that they
received support from their work environment, especially
when they showed an open and transparent attitude with
regard to their condition. Concerning their treating health
professionals (i.e., physician, pharmacist, nurse, and gen-
eral practitioner), their capabilities, mutual trust, and
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empathy were considered crucial for treatment. Especially
in long-term conditions, bonding with health professionals
was found by the patients to be beneficial and recom-
mended with regard to adherence. Furthermore, reim-
bursement and clear information about the medication
that is provided by the health insurance companies
were mentioned as facilitators of adherence. As a bar-
rier, the patients mentioned a lack of support, specific-
ally incomprehension by colleagues and subsequent
negative reactions.
Motivation
Motivation, the third COM-B component, reflects brain
processes that energize and direct behaviour [45]. Motiv-
ation encompassed the following domains: Beliefs about
Capabilities, Beliefs about Consequences, Emotions, and
Motivation and Goals.
Beliefs about capabilities
This domain represents the patients’ beliefs about their
own capabilities, such as believing they are able to
manage their condition (self-efficacy). Having good
overall health status (apart from IA) and using aids (to
remember to take their medication) were mentioned as
facilitators to strengthen their belief in their ability to
use DMARDs. Social and work events, a lack of a daily
routine, worse health status, difficulties administering
the medications (such as how to inject them), experien-
cing side effects, and doubting their own knowledge
about their medications were mentioned as barriers.
Beliefs about consequences
Strong beliefs about the beneficial effects of treatment
and believing that they are able to participate better in
social activities and work were mentioned as facilitators
to medication adherence. The following items were
mentioned as barriers: fear, feelings of doubt of efficacy
of medication, feelings of desire to stop treatment to be
free of the ongoing dependency on medication, feelings
of insecurity about the long-term effects, and non-
acceptance of the IA diagnosis.
Emotions
In contrast to the basic negative emotions (fear, anger,
and sadness) and other negative feelings (Table 3) that
were often mentioned as barriers to medication adher-
ence, positive emotions (joy, feelings of gratitude, hope,
and confidence) were rarely mentioned with regard to
DMARD use.
“I am worried about my organs, such as my heart, my
liver and my kidneys. It is toxic, everything I need to
take. I cannot imagine that my body can tolerate it for
many years. So, that is my biggest fear….” Female,
51 years, diagnosed with RA in 2014
Motivation and goals
Facilitators of adherence that were mentioned in this
domain, were experiencing a positive effect of the medi-
cation and being able to maintain autonomy, social
participation, and work participation, leading to im-
provements in quality of life. The patients were well
aware that treatment options have significantly better
health outcomes these days, which motivates them to
take their medications. Moreover, being able to hold
grandchildren, being able to do volunteer work, or being
able to keep their jobs were essential facilitators as well.
Patients were taking their medication to please their
physician to strengthen the relationship. A longer life ex-
pectancy was also considered a facilitator with regard to
adherence. Patients expressed feeling resistant toward
taking their medication, especially patients who already
felt down because of the long-term nature of their con-
dition. More practical issues surfaced as barriers, such as
a lack of a daily routine, worse health status (not feeling
well, besides the IA), fear of side effects, and difficulty
administering the medication (use of injections). Espe-
cially the elderly patients, expressed that their regimen
was sometimes perceived as too complex, resulting in
non-adherence.
Goal conflicts arose in situations in which the taking
of DMARDs interfered with the patients’ valued goals.
The barriers that were identified with regard to goal
conflict included experiencing side effects (and therefore
sometimes not being able to participate socially or in a
work environment), not being able to consume alcohol
while taking their medication (and therefore sometimes
feeling restricted in social contexts), not feeling well
physically and mentally (besides the IA) and therefore
not willing to take the medication, perceiving a lack of
social support, and being distracted from taking the
medication. Especially during holidays, of which the goal
is to relax and enjoy, when there is a lack of a routine,
adhering to treatment was found to be difficult, and
could lead to ambivalent feelings:
“…I always eat my breakfast before the intake of my
medication. During holidays, the routine is gone, so a
holiday is always positive and nice, but also a little bit
negative….” Male, 51 years, diagnosed with Psoriasis
and RA in 2001
However, some facilitators accommodated the intake
of DMARDs without interfering with the patients’ goals.
When taking the medication was firmly embedded in a
daily routine, it was easier to adhere to DMARD use. In-
strumental support, such as aids (week boxes or a phone
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alarm), to stimulate adherence was considered helpful.
Social support from family, friends, health professionals,
and colleagues also strengthened adherence behaviour.
Social relatives may emphasize the importance of con-
tinuing to use the medications despite interfering with a
goal that is set by the patient and especially the long-
term benefits. Patients mentioned that an easy way to
administer their medication, such as intravenously, or a
low frequency of use, helped them to be adherent with-
out causing goal conflicts. The less effort the patient has
to expend is associated with a higher probability of ad-
herent behaviour.
Discussion
The barriers and facilitators that were reported by IA pa-
tients in the present study presented large inter-individual
variations. The barriers and facilitators were identified
using the following domains of the existing adapted ver-
sion of the TDF for medication adherence [25, 40]: (i)
knowledge, (ii) emotions, (iii) attention, memory, and de-
cision processes, (iv) social influences, (v) beliefs about
capability, (vi) beliefs about consequences, (vii) motivation
and goals, (viii) goal conflict, (ix) environmental context
and resources, and (x) skills. These domains, originally de-
veloped to identify medication adherence barriers, appear
to be useful for also identifying medication adherence
facilitators. In the present study, in addition to using the
adapted domains of the TDF, the Behaviour Change
Wheel helped categorize all the identified barriers and
facilitators under the three elements of the Behaviour
Change Wheel (COM-B). Patients should have the oppor-
tunity to take their medication, should be motivated to
take their medication, and be capable of taking their
medication. Because the Behaviour Change Wheel can be
effectively used in a process of designing and implement-
ing intervention tools [45], categorization of the identified
barriers and facilitators using the domains of an adapted
TDF and the Behaviour Change Wheel elements may en-
hance the future development and implementation of an
intervention for adherence.
Most facilitators and barriers that were found in the
present study were comparable to factors that were related
to adherent and non-adherent behaviour in other studies
of long-term diseases. Two recently published reviews
summarized quantitative data on facilitators and barriers
in patients with RA [16, 26], and some similarities with
the present results were found. A good patient-health pro-
fessional relationship, knowledge about treatment, the ab-
sence of negative effects, an easy treatment regimen,
patients’ belief that they are able to fulfil the therapy, and
an appropriate amount of information that is provided by
the healthcare provider appear to improve adherence.
Consistent with these two previous reviews, barriers that
resulted in non-adherence in the present study included
not believing in the necessity of antirheumatic medication,
a busy lifestyle, and receiving contradictory information
from the healthcare provider. In contrast, the finding that
poorly developed health services with inadequate or non-
existent reimbursement may stimulate non-adherent be-
haviour was not evident in our study. The latter might be
explained by the fact that good health insurance is avail-
able to all patients in The Netherlands.
According to our qualitative study, barriers and facili-
tators that were mentioned by the patients as related to
adherence and non-adherence but were found not to be
statistically significant in the previous reviews were cop-
ing, immediacy of side-effects, perceived effectiveness of
the medication (outcome expectation), lack of belief in
benefit, number of medications, level of Methotrexate
dose, change in appearance of the medication, social
support, and improvement in quality of life.
One explanation for the different findings between
the present study and the previous reviews may be re-
lated to the type of study (i.e., qualitative vs. quantita-
tive research). In the present qualitative study, the
patients were free to write down their own experiences
as answers to open-ended questions. In the focus
groups, discussions that were based on individual opin-
ions were held freely, which contributed to a variety of
answers and reflected barriers and facilitators to medi-
cation adherence. The previous reviews consisted of
quantitative studies, in which different factors were
mentioned as statistically related or unrelated to adher-
ence and non-adherence.
The present study provided an overview of many differ-
ent barriers and facilitators with regard to DMARD use in
IA patients. Such various opinions were attributable to the
fact that we used an adapted Theoretical Domain Frame-
work with all its domains, thus offering patients the op-
portunity to identify many different factors that may
influence their adherence and non-adherence. Most of the
patients’ barriers and facilitators were captured by the
TDF, which may contribute to developing useful, effective,
tailor-made interventions for individual IA patients to
stimulate adherence.
All barriers or facilitators that the patients mentioned
could be categorized under one of the domains of the
adapted TDF, suggesting that this framework is helpful
for identifying barriers and facilitators of medication
adherence. Another strength of the TDF is the combin-
ation of cognitive and behavioural constructs with
appropriate implementation strategies from the Behav-
iour Change Wheel [45]. The Behaviour Change Wheel
comprises three elements—capability, opportunity, and
motivation—that may help identify types of interven-
tions that may be suitable for addressing the barriers
and facilitators of medication adherence in future
studies.
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A few limitations of the present study should be men-
tioned. First, selection bias could have occurred because
non-adherent patients might have been less willing to
participate in the study. To determine whether selection
bias occurred, all of the respondents (n = 120) completed
the CQR to assess medication adherence. The rate of ad-
herence was 67.5 %. This represents a comparable rate
of adherent and non-adherent respondents compared
with previous studies on medication adherence in RA,
which limits the possibility of selection bias [15–17].
Second, the response rate for the questionnaire was
modest, 42 %. A possible explanation for this modest re-
sponse could be that it was rather time consuming to
complete the questionnaire with open-ended questions
and the CQR. Because of the applied methodology, it
was not possible to examine whether responders of the
questionnaire differed from the non-responders in this
study nor whether this could have influenced our find-
ings. This approach was chosen to guarantee anonymity,
to emphasize the aim of this study to identify barriers
and facilitators to DMARD use, and to keep the already
long questionnaire feasible to fill out.
Third, the present study may have limited generalizability.
We only included Caucasian patients from one region
in The Netherlands. None of the participants were from
other ethnic backgrounds or represented various religions.
Therefore, potential difficulties in taking medications be-
cause of cultural or religious reasons (e.g., Ramadan) were
not mentioned in this study. Future studies should include
patients with different ethnicities and different religions
and from different regions to confirm the present
findings.
Fourth, the domains that were used in the present
study were previously established. One point of criticism
may be that the domains that were introduced to the pa-
tients may have led them to specific responses. However,
in the design of our study, we anticipated this possible
shortcoming and added an extra question: “Is there
anything that influences the use of your medication that
is not represented by one of the presented domains?”
Some of the patients mentioned additional barriers and
facilitators, but these could be categorized under one of
the existing domains. The fact that all of the barriers
and facilitators could be categorized into one of the
domains of the TDF indicates the usefulness of this
framework for capturing all barriers and facilitators that
are important for IA patients in the use of DMARDs.
Fifth, patterns or relationships between the theoretical
domains of the TDF are not specified within the TDF
framework, in contrast to other theoretical models of
behaviour, such as the Theory of Planned Behaviour
[36]. The use of the TDF framework in the present study
was specifically meant to capture as many barriers and
facilitators as possible with regard to adherence, without
exploring the relationships between domains or weight of
individual domains. Future studies should explore these
relationships and their relative weight with regard to bar-
riers and facilitators of medication adherence. Because we
used a different approach, the present study was not an at-
tempt to replace existing behavioural theories.
Conclusions
The patients in the present study identified a large var-
iety of barriers and facilitators of DMARD use. All the
identified facilitators and barriers fit in the domains of
an existing adapted version of the TDF. Therefore, the
TDF appears to be an appropriate framework for sys-
tematically assessing drivers that influence adherence
and non-adherence to the use of DMARDs. However,
further research is necessary to provide insights into (i)
the frequency and impact of different barriers and facilita-
tors on adherence, (ii) the development of tools to detect
facilitators and barriers in individual patients, and (iii) the
extent of modifiability of barriers and reinforcement of fa-
cilitators. This is essential before an intervention can be
designed, implemented, and evaluated for IA patients with
regard to DMARD use.
Practice implications
The present study was one step toward developing an
intervention to optimize DMARD use in IA patients.
Given the fact that the nature of the identified facilitators
and barriers of medication adherence is very heteroge-
neous, interventions that improve adherence should con-
sist of an inventory of patient’s individual barriers and
facilitators, followed by an intervention that is tailored to
individual patient needs. The Behaviour Change Wheel
may be beneficial as a guiding model in this process.
Furthermore, the present study shows that the TDF
framework is a useful tool for assessing patients’ individual
facilitators and barriers.
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